Novo Nordisk Diabetes Innovation Award Program

Novo Nordisk is offering a research award program to support both new and established scientists exploring novel hypotheses involving protein-based therapeutics and technologies for diabetes and obesity. The aim of this new program is to help scientists substantiate early innovation research efforts and clarify if their hypotheses have the potential to result in the cure, prevention, or improved treatment of diabetes and obesity.

The award program scope includes novel research ideas which, despite having potentially high impact, would not normally attract funding from such institutions as the National Institutes of Health.

Under the program, Novo Nordisk offers two types of research funding opportunities: "Early Exploration" and "Proof of Principle" awards. Both awards can support research projects for up to two years. Direct research expenses up to $500,000 USD will be covered. On top of the direct research costs, the awards cover the host institution's standard indirect costs (facilities and administrative). The award period is two years, but can be extended.

Awards cover non-clinical exploration of new biologics (protein-based) research and novel effects within all disease stages. Translational research (bed to bench) is eligible for support. The Annual Request for Proposals solicits proposals within the following areas:

  • T1D and T2D research, including microvascular complications (including diabetes late stage complications)
  • Obesity research
  • New biological ligands and targets, including large peptide or protein ligands (includes mAb’s, immunointervention, and cell-based therapies)
  • Novel effects of known proteins
  • Inhibitory or modulating antibodies
  • Immunotherapies
  • Small interfering RNAs
  • Cell-based concepts (e.g. stem cells)

The deadline for submissions is August 1, 2012. For more information, click here and contact Scott Steele, Ph.D., at scott.steele@rochester.edu.

 

 

 

NIH Funding Acknowledgement ** Important ** All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH FUNDING ACKNOWLEDGEMENT and must comply with the NIH Public Access Policy.